Touraine J L
Department of Transplantation & Clinical Immunology, Hôpital Edouard Herriot, Lyon, France.
J Hematother. 1996 Apr;5(2):195-9. doi: 10.1089/scd.1.1996.5.195.
Based on our experience in the field of fetal liver transplantation (FLT) that we have developed since 1976, we initiated, in 1988, in utero FLT into human fetuses, taking advantage of the immunologic tolerance in young fetuses. The transplants have involved fetuses suffering from various diseases at 12-28 weeks postfertilization, with 2 of the 6 cases eventually resulting in abortion. With the 4 other fetuses, a favorable outcome was observed. Three children are more than 4 years old, and they are alive and well, with evidence of engraftment, reconstitution of immunity, and partial correction of beta-thalassemia. In the fourth case, the fetus is alive and well and birth is expected soon. In utero transplantation of stem cells is a therapy with remarkable advantages: (a) tolerance induction due to immune immaturity of the host, (b) lack of graft-versus-host disease (GVHD) due to immaturity of the donor, (c) ideal isolation of the fetus in the maternal uterus, and (d) optimal environment for donor fetal cell development in the vicinity of host fetal cells and growth factors.
基于我们自1976年以来在胎儿肝移植(FLT)领域积累的经验,我们于1988年开始对人类胎儿进行宫内FLT,利用年轻胎儿的免疫耐受性。这些移植手术涉及受精后12至28周患有各种疾病的胎儿,6例中有2例最终流产。对于其他4例胎儿,观察到了良好的结果。3名儿童已超过4岁,他们存活且状况良好,有植入、免疫重建以及β地中海贫血部分纠正的证据。在第4例中,胎儿存活且状况良好,预计很快出生。宫内干细胞移植是一种具有显著优势的治疗方法:(a)由于宿主免疫不成熟而诱导耐受性;(b)由于供体不成熟而缺乏移植物抗宿主病(GVHD);(c)胎儿在母体子宫内得到理想的隔离;(d)在宿主胎儿细胞和生长因子附近为供体胎儿细胞发育提供最佳环境。